Download App

Log in to access Online Inquiry
Company Overview More
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company’s products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin’s lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
CEO: Robin, Howard W.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

NKTR Nektar Therapeutics
3.570-0.310-7.99%
Post Mkt Price
3.560-0.0099-0.28%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
-35.7% 667.03M -30.88% 733.96M -30.88% 733.96M -3.65% 921.08M
-Cash and cash equivalents
-54.72% 67.99M -87.32% 25.22M -87.32% 25.22M -3.27% 54.02M
-Short-term investments
-32.48% 599.03M -17.87% 708.74M -17.87% 708.74M -3.68% 867.06M
Receivables
3.65% 30.22M -42.16% 22.49M -42.16% 22.49M -32.45% 28.99M
-Accounts receivable
3.65% 30.22M -42.16% 22.49M -42.16% 22.49M -32.45% 28.99M
Inventory
-8.5% 15.38M 3.33% 15.8M 3.33% 15.8M 18.91% 15.33M
Other current assets
32.08% 20.83M 29.48% 23.33M 29.48% 23.33M -3.8% 20.73M
Total current assets
-33.26% 733.46M -30.09% 795.58M -30.09% 795.58M -5.53% 986.14M
Non current assets
Net PPE
-4.47% 175.28M -4.62% 177.54M -4.62% 177.54M -5.62% 178.54M
-Gross PPE
-4.47% 175.28M 0.29% 325.57M -4.62% 177.54M -5.62% 178.54M
-Accumulated depreciation
-- -- -6.9% -148.04M -- -- -- --
Goodwill and other intangible assets
0% 76.5M 0% 76.5M 0% 76.5M 0% 76.5M
-Goodwill
0% 76.5M 0% 76.5M 0% 76.5M 0% 76.5M
Investments and advances
-61.12% 37.36M -52.56% 64.83M -52.56% 64.83M -82.69% 34.22M
Other non current assets
5.99% 1.52M 87.82% 2.74M 87.82% 2.74M 29.86% 1.84M
Total non current assets
-18.7% 290.66M -19.75% 321.61M -19.75% 321.61M -37.37% 291.11M
Total assets
-29.69% 1.02B -27.4% 1.12B -27.4% 1.12B -15.34% 1.28B
Liabilities
Current liabilities
Payables
-43.76% 12.62M -55.97% 9.75M -55.97% 9.75M 52.8% 23.66M
-accounts payable
-43.76% 12.62M -55.97% 9.75M -55.97% 9.75M 52.8% 23.66M
Current accrued expenses
-18.58% 50.41M -35.06% 42.28M -35.06% 42.28M 0.05% 65.69M
Current debt and capital lease obligation
24.28% 19.6M 25.34% 17.44M 25.34% 17.44M 15.59% 17.74M
-Current capital lease obligation
24.28% 19.6M 25.34% 17.44M 25.34% 17.44M 15.59% 17.74M
Current liabilities
-14.84% 105.28M -26.41% 85.2M -26.41% 85.2M 10.65% 139.97M
Non current liabilities
Long term debt and capital lease obligation
-8.86% 122.64M -7.8% 125.74M -7.8% 125.74M -7.41% 128.72M
-Long term capital lease obligation
-8.86% 122.64M -7.8% 125.74M -7.8% 125.74M -7.41% 128.72M
Derivative product liabilities
-- 0 -- 27.73M -- 27.73M -- 21.39M
Other non current liabilities
-5.5% 188.31M -3.79% 199.02M -98.26% 3.59M 166.44% 185.63M
Total non current liabilities
-8.12% 310.95M 1.96% 352.48M 1.96% 352.48M 58.98% 335.73M
Total liabilities
-9.92% 416.23M -5.16% 437.68M -5.16% 437.68M 40.87% 475.7M
Shareholders'equity
Share capital
5.56% 19K 5.56% 19K 5.56% 19K 0% 18K
-common stock
5.56% 19K 5.56% 19K 5.56% 19K 0% 18K
-Preferred stock
-- 0 -- 0 -- 0 -- 0
Retained earnings
-20.2% -2.92B -22.69% -2.83B -22.69% -2.83B -22.6% -2.69B
Paid-in capital
3.15% 3.54B 3.77% 3.52B 3.77% 3.52B 3.82% 3.49B
Gains losses not affecting retained earnings
-109.29% -6.53M -81.13% -4.16M -81.13% -4.16M -229.91% -3.56M
Total stockholders'equity
-38.88% 607.89M -36.92% 679.51M -36.92% 679.51M -31.55% 801.54M
Total equity
-38.88% 607.89M -36.92% 679.51M -36.92% 679.51M -31.55% 801.54M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%